DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
DBV Technologies S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 16, 2026
$8.97−0.08 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $3.89B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
22M
Shares held, 13F filers
Institutional holders
78
17 new, 10 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $15.51M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Artisan Investments GP LLC | 3,309,055 | 7.00% | 13G (passive) | Dec 31, 2025 |
| Baker Bros. Advisors (GP) LLC | 25,586,190 | 9.99% | 13D (active) amendment | Jan 12, 2026 |
| Phillip Gross | 22,272,884 | 7.31% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 20,469,392 | 8.80% | 13G (passive) amendment | Dec 31, 2025 |
| Raymond Debbane | 19,310,005 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| MPM BioImpact LLC | 18,331,420 | 6.20% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah | 18,288,220 | 5.80% | 13G (passive) | Jul 30, 2026 |
| EPIC Bpifrance | 17,455,376 | 9.40% | 13D (active) amendment | Oct 31, 2025 |
| Vivo Opportunity, LLC | 15,685,950 | 5.70% | 13G (passive) amendment | Jan 12, 2026 |
| Aaron Cowen | 15,176,015 | 9.90% | 13G (passive) | Apr 7, 2025 |
| Robert Atchinson | 14,614,449 | 9.99% | 13G (passive) | Jun 30, 2025 |
| Bpifrance S.A. | 14,086,283 | 6.80% | 13D (active) amendment | Dec 17, 2025 |
| Nimish Shah | 11,929,079 | 8.20% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DBVT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mpm Bioimpact LLC | 3,666,284 | – | $60.13M | −1,547,077 | 3.67% |
| Siren, L.L.C. | 1,857,362 | – | $30.46M | – | 0.62% |
| Vivo Capital, LLC | 1,844,758 | – | $30.25M | −822,811 | 2.76% |
| Perceptive Advisors LLC | 1,653,350 | – | $27.11M | +688,959 | 0.41% |
| Baker Bros. Advisors LP | 1,461,425 | – | $23.97M | – | 0.12% |
| Artisan Partners Limited Partnership | 1,372,851 | – | $22.51M | −846,535 | 0.04% |
| UBS Group AG | 1,313,439 | – | $21.54M | +1,233,902 | 0.00% |
| Morgan Stanley | 954,908 | – | $15.66M | +808,792 | 0.00% |
| Logos Global Management LP | 915,000 | – | $15.01M | New | 0.65% |
| Patient Square Capital LP | 909,474 | – | $14.92M | +215,940 | 2.31% |
| Octagon Capital Advisors LP | 574,200 | – | $9.42M | – | 0.85% |
| ADAR1 Capital Management, LLC | 528,295 | – | $8.66M | −484,571 | 0.40% |
| Ikarian Capital, LLC | 525,000 | – | $1.69M | – | 0.18% |
| Redmile Group, LLC | 410,440 | – | $6.73M | −80,900 | 0.45% |
| Duquesne Family Office LLC | 383,363 | – | $6.29K | – | 0.12% |
| Ameriprise Financial Inc | 378,497 | – | $6.21M | +147,080 | 0.00% |
| Millennium Management LLC | 267,783 | – | $4.39M | −51,176 | 0.00% |
| Elmind Capital, LP | 265,000 | – | $4.35M | – | 1.09% |
| Jane Street Group, LLC | 223,915 | – | $3.67M | +212,630 | 0.00% |
| Ishara Investments LP | 184,500 | – | $3.03M | +82,000 | 2.22% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 22M | 17 / 17 | 24 / 10 | 5M | 5M |
| Q1 2026 | 71 | 21M | 29 / 13 | 13 / 10 | 9M | 4M |
| Q4 2025 | 52 | 16M | 26 / 15 | 4 / 7 | 11M | 1M |
| Q3 2025 | 33 | 7M | 8 / 7 | 6 / 4 | 0M | 1M |
| Q2 2025 | 29 | 7M | 16 / 3 | 3 / 3 | 5M | 0M |
| Q1 2025 | 16 | 2M | 3 / 4 | 2 / 5 | 0M | 0M |
| Q4 2024 | 18 | 3M | 18 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DBVT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Artisan International Small-Mid Fund | 840,251 | – | $13.78M | 0.54% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 428,800 | – | $5.79M | 0.26% | Jul 31, 2026 |
| AdvisorShares Dorsey Wright ADR ETF | 43,663 | – | $716.07K | 1.72% | Jun 30, 2026 |
| U.S. Small Cap Equity Fund | 22,707 | – | $306.54K | 0.03% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,897 | – | $169.93K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 5,834 | – | $95.68K | 0.04% | Jun 30, 2026 |
| Steward Values Enhanced International Fund | 4,051 | – | $54.69K | 0.02% | Jul 31, 2026 |
| Lord Abbett Health Care Fund | 2,973 | – | $40.14K | 0.47% | Jul 31, 2026 |
| ActivePassive International Equity ETF | 2,245 | – | $42.88K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Daniel Tasse | CHIEF EXECUTIVE OFFICER, Director | 17,094 | Nov 24, 2025 |
| Pharis Mohideen | Chief Medical Officer | 144,531 | Jul 31, 2026 |
| Virginie Boucinha | Chief Financial Officer | 70,000 | Nov 24, 2025 |
| Kevin Michael Trapp | Chief Commercial Officer | 55,000 | Nov 24, 2025 |
| Philina Lee | Director | – | Apr 16, 2026 |
| Brothers Life Sciences LP Baker | Director | 1,200,369 | Jan 14, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 1,585,054 | Jan 14, 2026 |
| 667, L.P. | Director | – | Jan 14, 2026 |
| Felix Baker | Director | – | Jan 14, 2026 |
| Julian Baker | Director | – | Jan 14, 2026 |
| Bros. Advisors Lp Baker | Director | – | Jan 14, 2026 |
| Participations SA Bpifrance | – | 10,898,595 | Dec 19, 2025 |
| Investissement S.A.S. Bpifrance | – | 226,133 | Dec 19, 2025 |
| Des Depots Et Consignations Caisse | – | – | Dec 19, 2025 |
| SA Bpifrance | – | – | Dec 19, 2025 |
| Bpifrance EPIC | – | 7,529,502 | Dec 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Pharis Mohideen Chief Medical Officer | Jul 29, 2026 | Sale | −464 | $2.70 | $1.25K | 144,531 |
| Pharis Mohideen Chief Medical Officer | Jan 29, 2026 | Sale | −534 | $4.86 | $2.60K | 144,995 |
| Bpifrance EPIC – | Dec 18, 2025 | Sale | −1,292,103 | $4.19 | $5.41M | 7,303,369 |
| Bpifrance EPIC – | Dec 17, 2025 | Sale | −2,036,990 | $4.84 | $9.86M | 8,635,472 |
| Bpifrance EPIC – | Dec 17, 2025 | Sale | −40,000 | $5.28 | $211.20K | 8,595,472 |
| Pharis Mohideen Chief Medical Officer | Nov 21, 2025 | Award | +44,000 | – | – | 145,529 |
| Pharis Mohideen Chief Medical Officer | Nov 21, 2025 | Sale | −1,624 | $2.77 | $4.50K | 101,529 |
| Virginie Boucinha Chief Financial Officer | Nov 21, 2025 | Award | +32,000 | – | – | 70,000 |
| Kevin Michael Trapp Chief Commercial Officer | Nov 21, 2025 | Award | +55,000 | – | – | 55,000 |
| Pharis Mohideen Chief Medical Officer | Nov 20, 2025 | Sale | −6,496 | $2.88 | $18.71K | 103,153 |
| Pharis Mohideen Chief Medical Officer | Jul 29, 2025 | Sale | −464 | $2.22 | $1.03K | 109,649 |
| Pharis Mohideen Chief Medical Officer | May 22, 2025 | Sale | −397 | $1.84 | $730 | 110,113 |
| Pharis Mohideen Chief Medical Officer | Jan 30, 2025 | Sale | −600 | $0.85 | $510 | 110,510 |
| Pharis Mohideen Chief Medical Officer | Nov 25, 2024 | Sale | −565 | $0.57 | $322 | 111,110 |
| Pharis Mohideen Chief Medical Officer | Nov 22, 2024 | Sale | −342 | $0.53 | $181 | 111,675 |
| Pharis Mohideen Chief Medical Officer | Nov 21, 2024 | Sale | −2,350 | $0.54 | $1.27K | 112,017 |
| Pharis Mohideen Chief Medical Officer | Nov 21, 2024 | Award | +35,000 | – | – | 114,367 |
| Virginie Boucinha Chief Financial Officer | Nov 21, 2024 | Award | +19,000 | – | – | 38,000 |
| Pharis Mohideen Chief Medical Officer | Jul 29, 2024 | Sale | −1,785 | $0.98 | $1.75K | 79,367 |
| Pharis Mohideen Chief Medical Officer | May 24, 2024 | Sale | −660 | $1.36 | $898 | 81,152 |
| Pharis Mohideen Chief Medical Officer | May 22, 2024 | Sale | −382 | $1.38 | $527 | 81,812 |
| Daniel Tasse CHIEF EXECUTIVE OFFICER, Director | Mar 8, 2024 | Buy | +17,094 | $0.83 | $14.19K | 17,094 |
| Adora Ndu Director | Feb 6, 2024 | Buy | +1,825 | $0.89 | $1.62K | 1,825 |
| Pharis Mohideen Chief Medical Officer | Nov 22, 2023 | Sale | −2,245 | $1.74 | $3.91K | 82,194 |
| Pharis Mohideen Chief Medical Officer | Nov 20, 2023 | Award | +35,000 | – | – | 84,439 |
| Virginie Boucinha Chief Financial Officer | Nov 20, 2023 | Award | +19,000 | – | – | 19,000 |
| Timothy E. Morris Director | Aug 25, 2023 | Buy | +12,000 | $1.52 | $18.24K | 12,000 |
| Daniel B. Soland Director | Aug 1, 2023 | Buy | +15,000 | $1.62 | $24.30K | 20,000 |
| Pharis Mohideen Chief Medical Officer | May 24, 2023 | Sale | −469 | $3.54 | $1.66K | 49,439 |
| Pharis Mohideen Chief Medical Officer | Nov 24, 2022 | Sale | −1,792 | $2.88 | $5.16K | 49,908 |
| Pharis Mohideen Chief Medical Officer | Nov 21, 2022 | Award | +17,500 | – | – | 51,700 |
| Sebastien Robitaille Chief Financial Officer | Nov 21, 2022 | Award | +8,000 | – | – | 36,500 |
| Pharis Mohideen Chief Medical Officer | Jul 29, 2022 | Award | +10,000 | – | – | 34,200 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Jun 13, 2022 | Award | +1,252,432 | – | – | 1,585,054 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Jun 13, 2022 | Award | +10,622,568 | – | – | 14,575,984 |
| Sebastien Robitaille Chief Financial Officer | Nov 22, 2021 | Award | +5,000 | – | – | 28,500 |
| Pharis Mohideen Chief Medical Officer | Nov 22, 2021 | Award | +8,700 | – | – | 24,200 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.